Necitumumab

Necitumumab – lek biologiczny, ludzkie przeciwciała monoklonalne skierowane przeciwko receptorowi nabłonkowego czynnika wzrostu (EGFR). ^[1]. Cząsteczka jest w fazie badań klinicznych testowana w guzach litych i raku płuca.

Przypisy

Bibliografia

• D. Yee. Receptor kinase inhibitors target NSCLC: two antibodies and a small-molecule MET inhibitor.. „BioDrugs”. 25 (4), s. 271-3, Aug 2011. DOI: 10.2165/11592720-000000000-00000. PMID: 21815704. 
• M. Di Maio. Is there still room for large registrative trials in unselected cancer patients? The case of anti-epidermal growth factor receptor antibodies in advanced non-small-cell lung cancer.. „Expert Opin Biol Ther”. 11 (9), s. 1131-3, Sep 2011. DOI: 10.1517/14712598.2011.599799. PMID: 21806477. 
• R. Dienstmann, J. Tabernero. Necitumumab, a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancer.. „Curr Opin Investig Drugs”. 11 (12), s. 1434-41, Dec 2010. PMID: 21154125. 
• R. Pirker, M. Filipits. Monoclonal antibodies against EGFR in non-small cell lung cancer.. „Crit Rev Oncol Hematol”. 80 (1), s. 1-9, Oct 2011. DOI: 10.1016/j.critrevonc.2010.10.008. PMID: 21109448. 
• JM. Reichert. Antibody-based therapeutics to watch in 2011.. „MAbs”. 3 (1). s. 76-99. PMID: 21051951. 
• B. Kuenen, PO. Witteveen, R. Ruijter, G. Giaccone i inni. A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies.. „Clin Cancer Res”. 16 (6), s. 1915-23, Mar 2010. DOI: 10.1158/1078-0432.CCR-09-2425. PMID: 20197484. 
• A. Tomillero, MA. Moral. Gateways to clinical trials.. „Methods Find Exp Clin Pharmacol”. 30 (7), s. 543-88, Sep 2008. PMID: 18985183. 

Linki zewnętrzne

Badania kliniczne

• Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of BMS-663513 in Subjects With Advanced and/or Metastatic Solid Tumors, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT01471210  (ang.).